Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311347 | 0.89 | CYP1A2 (0.44) | CYP1A2SLC6A3CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3881607 | 0.83 | SLC6A3 (0.51) | SLC6A3ITGB1ITGA4 | |
| SCHEMBL13311342 | 0.81 | SRR (0.48) | ITGB1ITGA4 | |
| SCHEMBL6487486 | 0.81 | SRR (0.48) | ITGB1ITGA4 | |
| SCHEMBL11199439 | 0.78 | CYP1A2 (0.40) | CYP1A2SLC6A3CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16359763 | 0.77 | CYP1A2 (0.47) | CYP1A2SLC6A3CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7050550 | 0.75 | SIGMAR1 (0.39) | CYP1A2SLC6A3ITGB1ITGA4SIGMAR1 | |
| Cyclohexylamine SCHEMBL8637515 | 0.75 | SRR (0.45) | ITGB1ITGA4 | |
| SCHEMBL15879424 | 0.73 | CYP1A2 (0.53) | CYP1A2CYP3A4CTSB | |
| SCHEMBL16912734 | 0.72 | CYP1A2 (0.48) | CYP1A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513188-B2 | Formulations comprising cyclic compounds | CAPSUGEL BELGIUM (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8513188-B2 | Formulations comprising cyclic compounds | CAPSUGEL BELGIUM (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | SLC2A1, SLC2A4, SLC2A9 | CYP1A2 3276/4885SLC6A3 400/4885CYP3A4 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.